Johnson & Johnson announces data to support boosting its single-shot COVID-19 vaccine

Johnson & Johnson announced this morning data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine.
In anticipation of the potential need for boosters, the company conducted two Phase 1/2a studies in individuals previously vaccinated with its single-shot vaccine.
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson COVID-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination, Johnson & Johnson says.
Significant increases in binding antibody responses were observed in participants between ages 18 and 55, and in those 65 years and older who received a lower booster dose.